Patent ID: 7300917

Claim:
A pharmaceutical composition comprising an EDG-2 antagonist in combination with one or more selected from LPA receptor antagonist, anti-androgenergic agent, α1 receptor blocker or 5α-reductase inhibitor, wherein the EDG-2 antagonist is a β-alanine derivative of formula (I) wherein A a is, (1) C1-6 alkeylene, (2) C2-6 alkenylene, or (3) C2-6 alkynylene, wherein A a may be substituted with 1-3 of C1-4 alkyl, Cyc1 a is, (1) C3-15 carboring, or (2) 3-15 membered heteroring having 1-4 of nitrogen, 1-2 of oxygen and/or 1-2 of sulfur, R 1a is (1) C1-4 alkyl, (2) halogen, (3) cyano, (4) trihalomethyl, (5) —OR 6a , (6) —SR 7 , (7) —NR 8a R 9a , (8) nitro, (9) —COOR 10a , (10) —CONR 11a R 12a , (11) —NR 13a COR 14a , (12) —SO 2 NR 15a R 16a , (13) —NR 17a SO 2 R 18a , (14) —S(O)R 19a , or (15) —SO 2 R 20a , R 6a , R 7a , R 8a , R 9a , R 10a , R 11a , R 12a , R 13a , R 14a , R 15a ,R 16a , R 17a , R 18a , R 19a and R 20a are each independently, (1) hydrogen, or (2) C1-4 alkyl, R 2a and R 3a are each independently, (1) C1-4 alkyl, (2) C1-4 alkoxy, or (3) halogen, R 4a and R 5a are each independently, (1) hydrogen, (2) C1-4 alkyl, (3) C2-4 alkenyl, (4) C2-4 alkynyl, (5) C1-4 alkyl substituted with —OR 21a , (6) C1-4 alkyl substitute with —NR 22a R 23a or R 4a and R 5a are taken together with the nitrogen to which they are attached to form a 3-15 membered mono-, bi- or tri-cyclic heteroring, wherein the heteroring represents at least one nitrogen and it may be substituted with C1-4 alkyl substituted with —OR 25a , R 21a , R 22a , R 23a and R 25a are each independently, (1) hydrogen, (2) C1-4 alkyl, (3) C2-6 acyl, or (4) trihaloacetyl, E a is (1) a bond, (2) C1-6 alkylene, (3) C2-6 alkenylene, or (4) C2-6 alkynylene, wherein E a may be substituted with 1-3 of (1) C1-4 alkyl, or (2) C1-4 alkyl substituted with —OR 26a , R 26a is (1) hydrogen, (2) C1-4 alkyl, (3) C2-6 acyl, or (4) trihaloacetyl, Cyc2 a is (1) C3-15 carboring, or (2) 3-15 metered heteroring having 1-4 of nitrogen, 1-2 of oxygen and/or 1-2 of sulfur, R 24a is (1) C1-4 alkyl, (2) halogen, (3) cyano, (4) trihalomethyl, (5) —OR 27a ,(6) —SR 28a , (7) —NR 29a R 30a , (8) nitro, (9) —COOR 31a , (10) —CONR 32a R 33a , (11) —NR 34a COR 35a , (12) —SO 2 NR 36a R 37a , (13) —NR 38a SO 2 R 39a ,(14) —S(O) 2 R 40a , or (15) —SO 2 R 41a , R 27a , R 28a , R 29a , R 30a , R 31a , R 32a , R 33a , R 34a , R 35a , R 36a , R 37a , R 38a , R 39a , R 40a and R 41a are each independently (1) hydrogen, or (2) C1-4 alkyl, ia is 0 or an integer of 1 to 5, ma is 0 or an integer of 1 to 4, and na is 0 or an integer of 1 to 4, pa is 0 or an integer of 1 to 5, and wherein when ia is 2 or more, R 1a 's are the same or different, when ma is 2 or more, R 2a 's are the same or different, when na is 2 or more, R 3a 's are the same or different, and when pa is 2 or more, they are the same or different, or a prodrug thereof or a salt thereof.